Registry of patients with connective tissue diseases and lung issues

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry aims to collect comprehensive clinical data on the incidence, prevalence, and progression of interstitial lung disease (ILD) and pulmonary hypertension (PH) in patients with connective tissue diseases (CTD) in Western Austria. Over a period of 10 years, the study will gather demographic information, clinical data, laboratory values, and therapeutic management details. Additionally, blood samples will be collected from a subgroup of patients with systemic sclerosis for translational research to explore inflammatory and fibrotic patterns. The goal is to better understand the disease course and identify potential therapeutic interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The inclusion criteria are adult patients (≥18 years) diagnosed with CTD with signed informed consent.

Exclusion Criteria:

* Exclusion criteria are patients with a serious co-morbidity interfering with the course of interstitial lung disease or pulmonary hypertension.

Where it's running

• Medical University Innsbruck, Department of Internal Medicine II
  Innsbruck, Austria Recruiting

Study contacts

• Principal investigator: Judith Löffler-Ragg, Prof. MD — Medical University Innsbruck, Department Internal Medicine
• Study coordinator: Magdalena Aichner, MD
• Email: magdalena.aichner@i-med.ac.at
• Phone: +43 512-504-83765

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early detection of progressive lung fibrosis in connective tissue diseases

  This project will test whether blood extracellular vesicle biomarkers combined with AI-analyzed HRCT scans can detect and predict progressive interstitial lung disease in adults with connective tissue diseases.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07541638

• Using capillaroscopy to help diagnose diffuse interstitial pneumonias

  We will test whether adding nailfold capillaroscopy to standard care helps doctors diagnose connective-tissue–related interstitial lung disease faster in adults newly diagnosed with pulmonary interstitial disease.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT07283081

• Understanding genetic and environmental factors in pulmonary fibrosis

  This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.

  Recruiting Royal College of Surgeons, Ireland · Dublin · NCT06702228

• Using stem cells to treat lung disease in patients with connective tissue disorders

  This study is testing if a new treatment using stem cells can help improve lung function in patients with lung disease caused by connective tissue disorders.

  Recruiting Phase 1/2 China Medical University Hospital · Taichung · NCT06574581

• Nintedanib plus tocilizumab for systemic sclerosis with interstitial lung disease

  This trial will test whether combining nintedanib and tocilizumab helps adults with systemic sclerosis and interstitial lung disease do better than standard treatments over 56 weeks.

  Recruiting Phase 3 National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland · Warsaw, Masovian Voivodeship · NCT06297096

• Using Mycophenolate Mofetil for Systemic Sclerosis with Mild Lung Issues

  This study is testing if a medication called mycophenolate mofetil can help people with systemic sclerosis and mild lung problems feel better over 96 weeks.

  Recruiting Phase 2 Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Quebec and 2 other locations · NCT05785065

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.